Jose Carmona
Known title: Chief Financial OfficerCIK: 0001693612
Associated companies
Transaction History
| ADCT | ▲ Buy | Grant | 203,700 | $0 | 6/30/2026 | View on chart |
| ADCT | ▲ Buy | Grant | 271,600 | $1.1M | 2/13/2026 | View on chart |
| ADCT | ▼ Sell | Tax Withholding | 25,880 | $103K | 2/13/2026 | View on chart |
| ADCT | ▼ Sell | Tax Withholding | 53,236 | $175K | 12/6/2025 | View on chart |
| ADCT | ▲ Buy | Grant | 240,000 | $386K | 2/13/2025 | View on chart |
| ADCT | ▼ Sell | Tax Withholding | 48,108 | $151K | 12/6/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
ADC Therapeutics Announces $86.6M Financing and Loan Amendments
ADC Therapeutics has secured $86.6 million through a private placement of 12.9 million shares at $1.42 each, along with warrants for 48.1 million shares. The company also amended its existing loan and royalty agreements. This capital raise provides additional liquidity to support operations, occurring while the stock trades near the top of its recent range.
ADC Therapeutics Announces $86.6M Financing and Loan Amendments. ADC Therapeutics has secured $86.6 million through a private placement of 12.9 million shares at $1.42 each, along with warrants for 48.1 million shares. The company also amended its existing loan and royalty agreements. This capital raise provides additional liquidity to support operations, occurring while the stock trades near the top of its recent range.